Evidence map›Paper›PMID 42118474›Full record

ArticleGeroScience2026

Elevated levels of circulating plasma sPDGFRβ in cognitively impaired APOE4 carriers.

Abhay P Sagare, Trevor Lohman, Ivan Ramirez, Elizabeth B Joe, Michael G Harrington, Helena C Chui, Lon S Schneider, Hussein N Yassine, John M Ringman, Arthur W Toga and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Abhay P SagareDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, 1501 San Pablo Street, Los Angeles, CA, 90089, USA.
Trevor LohmanLeonard Davis School of Gerontology, Keck School of Medicine, University of Southern California, 3715 McClintock Avenue, Los Angeles, CA, 90089, USA.
Ivan RamirezDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, 1501 San Pablo Street, Los Angeles, CA, 90089, USA.
Elizabeth B JoeAlzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Michael G HarringtonAlzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Helena C ChuiAlzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Lon S SchneiderAlzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Hussein N YassineAlzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
John M RingmanAlzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Arthur W TogaAlzheimer's Disease Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Daniel A NationDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, 1501 San Pablo Street, Los Angeles, CA, 90089, USA. danation@usc.edu.
Berislav V ZlokovicDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, 1501 San Pablo Street, Los Angeles, CA, 90089, USA. zlokovic@usc.edu.

Funding

VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHUI, HELENA CHANG · 1985 to 2019
$41.0M
Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer's DiseaseP01AG052350 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Daniel A Nation, ARTHUR W TOGA · 2016 to 2026
$28.4M
NIA NIH HHS 5P01AG052350NIA NIH HHS 5P50AG005142NIA NIH HHS P01 AG052350NIA NIH HHS P50 AG005142
6 · The paper itself

Abstract

Increased levels of cerebrospinal fluid (CSF) soluble platelet-derived growth factor receptor-β (sPDGFRβ), a marker of blood-brain barrier (BBB)-associated pericyte cell injury, have been shown to correlate with increased BBB permeability and severity of Alzheimer's disease (AD) pathology. It has been also shown that increased CSF sPDGFRβ levels can predict cognitive dysfunction in APOE4 carriers bearing the main susceptibility gene for AD. Whether plasma sPDGFRβ levels are also elevated in APOE4 carriers has not been explored. Here, we analyzed plasma samples for sPDGFRβ levels, Ab

Indexed as

Alzheimer DiseaseApolipoprotein E4Cognition DisordersReceptor, Platelet-Derived Growth Factor betaAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersBlood-Brain BarrierFemaleHeterozygoteHumansMaleAmyloid beta-PeptidesApolipoprotein E4BiomarkersReceptor, Platelet-Derived Growth Factor betaAlzheimer's diseaseAPOE4Blood-brain barrierPericyte injurysPDGFRbeta

Identifiers

PMID42118474
PMCPMC13356018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.